| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
|
N Engl J Med
|
2015
|
5.86
|
|
2
|
Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen.
|
Clin Infect Dis
|
2006
|
3.05
|
|
3
|
The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial.
|
Pediatr Infect Dis J
|
2013
|
1.84
|
|
4
|
Evolutionary and functional relationships of colonization factor antigen i and other class 5 adhesive fimbriae of enterotoxigenic Escherichia coli.
|
Infect Immun
|
2004
|
1.68
|
|
5
|
Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
|
Clin Infect Dis
|
2013
|
1.48
|
|
6
|
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
|
Vaccine
|
2013
|
1.45
|
|
7
|
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
|
Vaccine
|
2013
|
1.39
|
|
8
|
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
|
Pediatrics
|
2010
|
1.36
|
|
9
|
Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.
|
Infect Immun
|
2002
|
1.34
|
|
10
|
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.
|
Pediatrics
|
2010
|
1.32
|
|
11
|
Donor strand complementation governs intersubunit interaction of fimbriae of the alternate chaperone pathway.
|
Mol Microbiol
|
2007
|
1.19
|
|
12
|
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
|
Clin Vaccine Immunol
|
2010
|
1.12
|
|
13
|
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.
|
Vaccine
|
2010
|
1.10
|
|
14
|
Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
|
Vaccine
|
2013
|
1.09
|
|
15
|
Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.
|
Infect Immun
|
2010
|
1.05
|
|
16
|
In vivo phase variation and serologic response to lipooligosaccharide of Campylobacter jejuni in experimental human infection.
|
Infect Immun
|
2004
|
1.05
|
|
17
|
13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine.
|
Pediatr Infect Dis J
|
2014
|
0.98
|
|
18
|
The epidemiology of self-reported diarrhea in operations Iraqi freedom and enduring freedom.
|
Diagn Microbiol Infect Dis
|
2004
|
0.97
|
|
19
|
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
|
Pediatr Infect Dis J
|
2012
|
0.94
|
|
20
|
Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine.
|
Ann N Y Acad Sci
|
2012
|
0.91
|
|
21
|
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India.
|
Pediatr Infect Dis J
|
2013
|
0.90
|
|
22
|
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
|
AIDS
|
2015
|
0.87
|
|
23
|
Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries.
|
Vaccine
|
2013
|
0.86
|
|
24
|
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines.
|
Pediatr Infect Dis J
|
2013
|
0.86
|
|
25
|
Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults.
|
Clin Vaccine Immunol
|
2012
|
0.84
|
|
26
|
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. An open-label trial.
|
Hum Vaccin Immunother
|
2014
|
0.83
|
|
27
|
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults.
|
Hum Vaccin Immunother
|
2015
|
0.83
|
|
28
|
Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial.
|
Pediatr Infect Dis J
|
2010
|
0.83
|
|
29
|
Campylobacter infection as a trigger for Guillain-Barré syndrome in Egypt.
|
PLoS One
|
2008
|
0.80
|
|
30
|
Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine.
|
Vaccine
|
2011
|
0.80
|
|
31
|
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.
|
Pediatr Infect Dis J
|
2013
|
0.80
|
|
32
|
Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States.
|
Pediatr Infect Dis J
|
2013
|
0.78
|
|
33
|
Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan.
|
Pediatr Infect Dis J
|
2015
|
0.78
|
|
34
|
Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared with Term Infants.
|
Pediatr Infect Dis J
|
2016
|
0.77
|
|
35
|
A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil.
|
Vaccine
|
2012
|
0.76
|
|
36
|
Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine.
|
Vaccine
|
2011
|
0.76
|
|
37
|
Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine.
|
Pediatr Infect Dis J
|
2013
|
0.76
|
|
38
|
Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China.
|
Pediatr Infect Dis J
|
2016
|
0.76
|
|
39
|
13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.
|
Vaccine
|
2013
|
0.75
|
|
40
|
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico.
|
Rev Panam Salud Publica
|
2013
|
0.75
|
|
41
|
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine manufactured with and without polysorbate 80 given to healthy infants at 2, 3, 4 and 12 months of age.
|
Pediatr Infect Dis J
|
2015
|
0.75
|
|
42
|
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine.
|
Pediatr Infect Dis J
|
2011
|
0.75
|
|
43
|
Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
|
Vaccine
|
2013
|
0.75
|
|
44
|
Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.
|
Vaccine
|
2013
|
0.75
|
|
45
|
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Children Aged 6 to 17 Years in India: An Open-Label Trial.
|
Pediatr Infect Dis J
|
2017
|
0.75
|
|
46
|
Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
|
Pediatr Infect Dis J
|
2014
|
0.75
|
|
47
|
13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
|
Pediatr Infect Dis J
|
2012
|
0.75
|
|
48
|
AL-12182, a novel 11-oxa prostaglandin analog with topical ocular hypotensive activity in the monkey.
|
Bioorg Med Chem Lett
|
2004
|
0.75
|